Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Angina in women linked with abnormal heart blood flow

Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.

12 Nov 2015

White coat hypertension, masked hypertension increase cardiovascular events over the years

Patients whose blood pressures spikes in the doctor's office but not at home, and patients whose blood pressure spikes at home but not in the doctor's office, suffer more heart attacks, heart failure, and strokes than patients with normal blood pressures in both settings, UT Southwestern Medical Center researchers have found.

10 Nov 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Upstream Medical Technologies formed to revolutionise accurate diagnosis of heart conditions

A new company that could revolutionise the accurate diagnosis of heart conditions was launched in Christchurch, New Zealand today.

29 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.

2 Sep 2015

Study: Depressed patients three times more likely to experience frequent chest pain

Depressed patients have more frequent chest pain even in the absence of coronary artery disease, according to results from the Emory Cardiovascular Biobank presented at ESC Congress today by Dr Salim Hayek, a cardiologist at Emory University School of Medicine in Atlanta, Georgia, US.

31 Aug 2015

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).

31 Aug 2015

Weather and pollution affect outcomes after heart attack

Pollution and weather influence outcomes after a heart attack, according to research presented at ESC Congress today by Ms Aneta Cislak, research fellow in the Silesian Centre for Heart Diseases, Medical University of Silesia in Zabrze, Poland.

29 Aug 2015

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology and European Respiratory Society.

29 Aug 2015

Nitroglycerin can be repurposed to treat cancer, researchers find

For over a century, nitroglycerin has been used medically - particularly in the treatment of angina, or chest pain. It is a safe, cheap and effective treatment. Now, according to the latest study in ecancermedicalscience, researchers find that nitroglycerin is the latest in a series of medicines that could be repurposed to treat cancer.

27 Aug 2015

Rehabilitation can improve prognosis for heart disease, reduce patient mortality

Rehabilitation is recommended for many patients following a hospital stay for acute heart disease. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztebl int 112: 527-34) Axel Schlitt et al. show that this improves prognosis for heart disease and can thus reduce patient mortality.

27 Aug 2015

Study shows that quitting smoking after heart attack improves mental health, quality of daily life

A new study shows that quitting smoking after a heart attack has immediate benefits, including less chest pain, better quality of daily life and improved mental health. Many of these improvements became apparent as little as one month after quitting and are more pronounced after one year, according to the research at Washington University School of Medicine in St. Louis.

26 Aug 2015

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease.

21 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

Angina News and Research

Further Reading

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Angina in women linked with abnormal heart blood flow

White coat hypertension, masked hypertension increase cardiovascular events over the years

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Upstream Medical Technologies formed to revolutionise accurate diagnosis of heart conditions

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Treatment with life-saving medications increases in IHD but levels still suboptimal

Study: Depressed patients three times more likely to experience frequent chest pain

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

Weather and pollution affect outcomes after heart attack

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

Nitroglycerin can be repurposed to treat cancer, researchers find

Rehabilitation can improve prognosis for heart disease, reduce patient mortality

Study shows that quitting smoking after heart attack improves mental health, quality of daily life

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Neovasc's second quarter revenues drop 18%

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News